A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States
A phase 2 trial of Tislelizumab, Capecitabine, Fluorouracil (5-FU) and Oxaliplatin in gastric & gastro-oesophageal junction cancer and oesophageal cancer, run by BeOne Medicines, now recruiting.
Overview
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States is a phase 2 interventional study registered as NCT07554521 by BeOne Medicines, with 30 participants planned, started 2026-04-30 and due to reach its primary completion in 2031-12-31. Interventions recorded: Tislelizumab, Capecitabine, 5-fluorouracil (5-FU), Oxaliplatin and Leucovorin.
Similar pages
not linked directly; found by shared links- TrialSubstudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Shares Fluorouracil (5-FU), Oxaliplatin, Capecitabine, Oesophageal cancer and the tag pipeline.
- TrialA Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Shares Tislelizumab, Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]
Shares Tislelizumab, Oxaliplatin, Capecitabine and the tag pipeline.
- TrialPh1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
Shares Fluorouracil (5-FU), Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Shares Fluorouracil (5-FU), Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialClinical Studies for the Treatment of Advanced Solid Tumors
Shares Tislelizumab, Oxaliplatin, Capecitabine and the tag pipeline.
- TrialA Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
Shares Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
Shares Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer and the tag pipeline.